Cargando…

Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib

BACKGROUND: Despite effective activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as erlotinib, all non-small cell lung cancer (NSCLC) patients eventually acquire resistance to these agents. Studies have demonstrated that down-regulation of miRNA-145 leads to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amri, Jamal, Molaee, Neda, Baazm, Maryam, Karami, Hadi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976848/ https://www.ncbi.nlm.nih.gov/pubmed/31554377 http://dx.doi.org/10.31557/APJCP.2019.20.9.2781

Ejemplares similares

MiRNA-Mediated Knock-Down of Bcl-2 and Mcl-1 Increases Fludarabine-Sensitivity in CLL-CII Cells
por: Ashofteh, Nooshin, et al.
Publicado: (2021)

Knockdown of Myeloid Cell Leukemia-1 by MicroRNA-101 Increases Sensitivity of A549 Lung Cancer Cells to Etoposide
por: Shahverdi, Mahshid, et al.
Publicado: (2021)

Up-Regulation of MiRNA-125a-5p Inhibits Cell Proliferation and Increases EGFR-TKI Induced Apoptosis in Lung Cancer Cells
por: Jamal, Jamal, et al.
Publicado: (2019)

MiRNA-7 Replacement Effect on Proliferation and Tarceva-Sensitivity in U373-MG Cell Line
por: Alamdari-Palangi, Vahab, et al.
Publicado: (2020)

Gene Therapy with MiRNA-Mediated Targeting of Mcl-1 Promotes the Sensitivity of Non-Small Cell Lung Cancer Cells to Treatment with ABT-737
por: Shahverdi, Mahshid, et al.
Publicado: (2020)

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
por: Zwitter, Matjaz, et al.
Publicado: (2016)

Heterologous expression of a truncated form of human recombinant vascular endothelial growth factor-A and its biological activity in wound healing
por: Khaki, Mohsen, et al.
Publicado: (2017)

Regulation of Epidermal Growth Factor Receptor Signaling and Erlotinib Sensitivity in Head and Neck Cancer Cells by miR-7
por: Kalinowski, Felicity C., et al.
Publicado: (2012)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Combination Therapy with PIK3R3-siRNA and EGFR-TKI Erlotinib Synergistically Suppresses Glioblastoma Cell Growth In Vitro
por: Amini, Razieh, et al.
Publicado: (2021)

Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
por: IWAI, TOSHIKI, et al.
Publicado: (2011)

TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin
por: Xiaobo, Cao, et al.
Publicado: (2016)

Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL
por: Iaboni, Margherita, et al.
Publicado: (2016)

PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy
por: Zhou, Xin, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor Inhibition with Erlotinib Partially Prevents Cisplatin-Induced Nephrotoxicity in Rats
por: Wada, Yukihiro, et al.
Publicado: (2014)

Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review
por: Jazieh, Abdul-Rahman, et al.
Publicado: (2013)

Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
por: Jabbari, Siavash, et al.
Publicado: (2011)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
por: Cavazzoni, Andrea, et al.
Publicado: (2012)

Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR-mutated NSCLC cells in vitro and in vivo via STAT3/Bcl-2 signaling
por: Zhou, Xiaowen, et al.
Publicado: (2021)

A Novel Insertion Mutation on Exon 20 of Epidermal Growth Factor Receptor, Conferring Resistance to Erlotinib
por: Khan, Nawazish A., et al.
Publicado: (2014)

The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma
por: Doyle, Sean P, et al.
Publicado: (2018)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
por: O’Leary, Connor, et al.
Publicado: (2020)

Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs
por: Farhan, Mohd, et al.
Publicado: (2019)

miRNA-101-5p inhibits the growth and aggressiveness of NSCLC cells through targeting CXCL6
por: Chen, Qi, et al.
Publicado: (2019)

Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells
por: Koyama, Satoshi, et al.
Publicado: (2015)

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small cell lung cancer (NSCLC) cells
por: Whang, Young Mi, et al.
Publicado: (2015)

RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
por: Nadal, Ernest, et al.
Publicado: (2021)

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene
por: Roberts, Melyssa S., et al.
Publicado: (2020)

Maintained Complete Response and Long-Term Survival in Epidermal Growth Factor Receptor Mutated Metastatic Non-Small Cell Lung Cancer with Erlotinib
por: Alkassis, Samer, et al.
Publicado: (2021)

Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib
por: Sorensen, Boe S, et al.
Publicado: (2014)

Role of miRNA-145, 148, and 185 and Stem Cells in Prostate Cancer
por: Coradduzza, Donatella, et al.
Publicado: (2022)

Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor
por: Nishimura, Toshio, et al.
Publicado: (2015)

Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
por: Wang, Jack P., et al.
Publicado: (2015)

Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine
por: Akiyama, Norimichi, et al.
Publicado: (2017)

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
por: Kobayashi, Kunihiko, et al.
Publicado: (2013)

Expression of miRNA-206 and miRNA-145 in breast cancer and correlation with prognosis
por: Quan, Yan, et al.
Publicado: (2018)

Expression and clinical significance of miRNA-145 and miRNA-218 in laryngeal cancer
por: Guo, Libing, et al.
Publicado: (2019)

miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor
por: ZHAO, FENG-YI, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1i96jjrmp2p5vbimoo6tl4fs00